{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:42:04Z","timestamp":1791236524731,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bpg.2025.101981","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:22:44Z","timestamp":1736360564000},"page":"101981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution?"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij","family":"Han\u017eel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Massimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bpg.2025.101981_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2025.101981_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.101981_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.101981_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ueg2.12366","article-title":"Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta\u2010analysis","volume":"11","author":"Magro","year":"2023","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"10.1016\/j.bpg.2025.101981_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-021-00555-w","article-title":"Precision medicine in IBD: genes, drugs, bugs and omics","volume":"19","author":"Mao","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2025.101981_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/17474124.2020.1772057","article-title":"Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach","volume":"14","author":"D'Amico","year":"2020","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101981_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101981_bib8","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2025.101981_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","article-title":"The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)","volume":"71","author":"Danese","year":"2022","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.bpg.2025.101981_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2025.101981_bib11","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.bpg.2025.101981_bib12","first-page":"1225","article-title":"Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats","volume":"26","author":"Bendele","year":"1999","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.bpg.2025.101981_bib13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/PL00000629","article-title":"Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats","volume":"57","author":"Feige","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bpg.2025.101981_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4176974","article-title":"Concomitant treatment with etanercept and tacrolimus synergistically attenuates arthritis progression via inhibition of matrix metalloproteinase-3 production and osteoclastogenesis in human TNF-\u03b1 transgenic mice","volume":"2019","author":"Seki","year":"2019","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.bpg.2025.101981_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13075-015-0866-0","article-title":"Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice","volume":"17","author":"Llop-Guevara","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bpg.2025.101981_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trsl.2021.01.004","article-title":"Efficacy of novel bispecific antibody targeting TNF-\u03b1\/CXCL10 in the treatment of experimental arthritis","volume":"232","author":"Kang","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.bpg.2025.101981_bib17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2025.101981_bib18","doi-asserted-by":"crossref","first-page":"i348","DOI":"10.1093\/ecco-jcc\/jjab232.455","article-title":"P328 in silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease","volume":"16","author":"Perrigoue","year":"2022","journal-title":"J Crohn's Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101981_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97236-0","article-title":"Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpg.2025.101981_bib20","article-title":"Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-\u03b1 and IL-23p19 bioactivities","volume":"4","author":"Wang","year":"2024","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.bpg.2025.101981_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111238","article-title":"Therapeutic potential of a synthetic dual JAK1\/TYK2 inhibitor in inflammatory bowel disease","volume":"126","author":"Cui","year":"2024","journal-title":"Int Immunopharm"},{"issue":"3","key":"10.1016\/j.bpg.2025.101981_bib22","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101981_bib23","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101981_bib24","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.bpg.2025.101981_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manip Physiol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.101981_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol : Official Clin Practice J Am Gastroenterol Associat"},{"key":"10.1016\/j.bpg.2025.101981_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission whil receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101981_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101981_bib29","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101981_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2025.101981_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103331","article-title":"Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: a systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Solitano","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bpg.2025.101981_bib32","article-title":"The future of clinical trials in inflammatory bowel disease","author":"Ma","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:38:30Z","timestamp":1754293110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691825000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S1521691825000083"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101981","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101981"}}